-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

BV and Beyond: How to Incorporate Novel Agents into PTCL Management

Program: Education Program
Session: Addressing Unmet Needs in T Cell Lymphomas
Hematology Disease Topics & Pathways:
Combination therapy, Lymphomas, Drug development, T Cell lymphoma, Diseases, Treatment Considerations, Lymphoid Malignancies
Monday, December 9, 2024, 4:30 PM-5:45 PM

Neha Mehta-Shah, MD

Siteman Cancer Center, Washington University in St. Louis, St Louis, MO

Disclosures: Mehta-Shah: Dizal Pharmaceuticals: Research Funding; Genetech/Roche: Consultancy, Research Funding; Morphosys: Research Funding; Celgene: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; C4 Therapeutics: Consultancy, Research Funding; Johnson & Johnson/Janssen: Consultancy; Innate Pharmaceuticals: Research Funding; Verastem Oncology: Research Funding; Pfizer: Consultancy; Secura Bio: Consultancy, Research Funding; Yingli Pharmaceuticals: Research Funding; Bristol Myers-Squibb: Research Funding; Astra Zeneca: Consultancy, Research Funding; Corvus Pharmaceuticals: Research Funding; Kyowa Hakko Kirin, Karyopharm Therapeutics: Consultancy.

OffLabel Disclosure: Duvelisib, tenalisib, liperlisib for PTCL. Golidicitinib for PTCL. Azacitidine for PTCL. Ruxolitinib for PTCL. Valemetostat, tulmiemtostat for PTCL. Soquelitinib for PTCL.

See more of: Addressing Unmet Needs in T Cell Lymphomas
See more of: Education Program
Previous Presentation | Next Presentation >>